Cargando…

A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen

BACKGROUND: Colorectal cancer is a major public health issue worldwide. Interleukin-17 (IL-17) and Th17 (T-helper cell type 17)-related molecules are involved in tumor development and in resistance to bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody used in association wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lereclus, Emilie, Tout, Mira, Girault, Alban, Baroukh, Nadine, Caulet, Morgane, Borg, Christophe, Bouché, Olivier, Ternant, David, Paintaud, Gilles, Lecomte, Thierry, Raoul, William
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368920/ https://www.ncbi.nlm.nih.gov/pubmed/28347290 http://dx.doi.org/10.1186/s12885-017-3210-z

Ejemplares similares

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
por: Mulleman, Denis, et al.
Publicado: (2011)

Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
por: Ducourau, Emilie, et al.
Publicado: (2011)

Expression Profiling of Calcium Channels and Calcium-Activated Potassium Channels in Colorectal Cancer
por: Ibrahim, Sajida, et al.
Publicado: (2019)

Revisiting myocardial necrosis biomarkers: assessment of the effect of conditioning therapies on infarct size by kinetic modelling
por: Ternant, David, et al.
Publicado: (2017)

17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
por: Bagacean, Cristina, et al.
Publicado: (2019)

Association of IgG1 Antibody Clearance with FcγRIIA Polymorphism and Platelet Count in Infliximab-Treated Patients
por: Thibault, Gilles, et al.
Publicado: (2021)

Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment—A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
por: Ternant, David, et al.
Publicado: (2021)

Kinetic modelling of myocardial necrosis biomarkers offers an easier, reliable and more acceptable assessment of infarct size
por: Chadet, Stéphanie, et al.
Publicado: (2020)

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma
por: Bertaut, Aurélie, et al.
Publicado: (2016)

Translation of Monoclonal Antibodies Pharmacokinetics from Animal to Human Using Physiologically Based Modeling in Open Systems Pharmacology (OSP) Suite: A Retrospective Analysis of Bevacizumab
por: Pasquiers, Blaise, et al.
Publicado: (2023)

Pectoralis major muscle atrophy is associated with mitochondrial energy wasting in cachectic patients with gastrointestinal cancer
por: Dolly, Adeline, et al.
Publicado: (2022)

Breakthrough Pain: The Importance of Baseline Analgesic Regimen with Opioids
por: Zampi, Maddalena, et al.
Publicado: (2012)

Clinical outcomes with bevacizumab-containing and non-bevacizumab–containing regimens in patients with recurrent glioblastoma from US community practices
por: Chen, Clara, et al.
Publicado: (2015)

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
por: Salimon, Maëva, et al.
Publicado: (2018)

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
por: Kast, Richard E.
Publicado: (2018)

Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma
por: Giovannini, Catia, et al.
Publicado: (2023)

Differential effects of interleukin-17A and 17F on cell interactions between immune cells and stromal cells from synovium or skin
por: Tout, Issam, et al.
Publicado: (2023)

Atypical Reversible Leucoencephalopathy Syndrome after Bevacizumab/Folfox Regimen for Metastatic Colon Cancer
por: Salmi, Narimane, et al.
Publicado: (2014)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer
por: Krüger, Kristi, et al.
Publicado: (2021)

Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
por: Mulleman, Denis, et al.
Publicado: (2009)

Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma
por: LAM, KA ON, et al.
Publicado: (2013)

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
por: Martinetti, Antonia, et al.
Publicado: (2014)

Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study
por: Coudert, Bruno, et al.
Publicado: (2020)

The combination of intravenous bevacizumab and metronomic oral cyclophosphamide is an effective regimen for platinum-resistant recurrent ovarian cancer
por: Barber, Emma L., et al.
Publicado: (2013)

Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients
por: Ozkaya, Abdullah, et al.
Publicado: (2013)

Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer
por: Mehrzad, Valiollah, et al.
Publicado: (2016)

COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
por: Kon, Takashi, et al.
Publicado: (2020)

Impact of Baseline Insulin Regimen on Glycemic Response to a Group Medical Clinic Intervention
por: Crowley, Matthew J., et al.
Publicado: (2013)

Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
por: Prager, Gerald W, et al.
Publicado: (2014)

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment
por: Hosoda, Shunichi, et al.
Publicado: (2022)

Cell Differentiation in a Bacillus thuringiensis Population during Planktonic Growth, Biofilm Formation, and Host Infection
por: Verplaetse, Emilie, et al.
Publicado: (2015)

Expression of the Bacillus thuringiensis vip3A Insecticidal Toxin Gene Is Activated at the Onset of Stationary Phase by VipR, an Autoregulated Transcription Factor
por: Chen, Haibo, et al.
Publicado: (2022)

Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens
por: du Rusquec, P., et al.
Publicado: (2023)

Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial
por: Ducourau, Emilie, et al.
Publicado: (2020)

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2012)

ANGI-01 ALTERATION IN IMMUNE REGULATORY CELLS BEFORE AND AFTER TREATMENT BY STUPP REGIMEN WITH OR WITHOUT BEVACIZUMAB FOR GLIOBLASTOMA
por: Tanaka, Toshihide, et al.
Publicado: (2019)

Response to 1-Year Fixed-Regimen Bevacizumab Therapy in Treatment-Naïve DME Patients: Assessment by OCT Angiography
por: Hunt, Magdalena, et al.
Publicado: (2022)

Atezolizumab plus platinum-based regimen and bevacizumab: is it time to consider immunotherapy in a concurrent approach for lung cancer?
por: Bianco, Andrea, et al.
Publicado: (2019)

Complementary roles of KCa3.1 channels and β1-integrin during alveolar epithelial repair
por: Girault, Alban, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ocabbkudfh4ooq003j879toci3